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j ourna l homepage: ht tp : / /www.e lsev ie r .com/ locate /ct rscBaroreﬂex activation therapy: A new avenue for heart failure treatment☆1. Background and ﬁrst-in-man experience
A central factor in the development of HF and progression to death is
deranged autonomic balance, characterized by elevated sympathetic ac-
tivity and diminished parasympathetic activity. In this context, barore-
ﬂex activation therapy (BAT) is a promising option for patients
suffering from advanced HF if one considers that reduced baroreﬂex
sensitivity (BRS) has been linkedwith poor outcome [2]. BAT is an active
implantable device therapy which electrically stimulates the carotid
baroreceptors using a system similar to a pacemaker [3]. In advanced
HF autonomic imbalance derives from excessive sympatho-excitatory
feedback from the cardiovascular system and from depressed mechan-
ical perturbation of carotid baroreceptors [1,2]. Comprehensive end-
organ protection cannot be achieved by blockade of cardiac beta-
adrenergic receptors and suppression of the renin-angiotensin-
aldosterone system. To succeed in this regard, the challenge has to be
taken to the root cause of autonomic imbalance. This is where BAT is in-
deed acting. Recently, positive results of ﬁrst-in-man and randomized,
controlled trials of BAT in HF with reduced ejection fraction (HFrEF)
have been published. Although these studies are by their nature not de-
ﬁnitive they have important implications for state-of-the-art HFrEF
management.
In our ﬁrst-in-man experience BAT chronically reducedmuscle sym-
pathetic nerve activity (MSNA), and improved a cardiac vagal marker
like BRS thus implying the possibility to restore autonomic balance by
speciﬁc receptor activation [4]. A strong rationale for a therapy that in-
creases reﬂex cardiac vagal control, as documented BRS analyses, is
found in the results of the ATRAMI trial [5] where post myocardial in-
farction patients with depressed LV function and preserved BRS experi-
enced longer event-free survival. Moreover, the effect of preserved BRS
appeared comparable and incremental to the beneﬁt of beta-blockade.
Thus, restoration of reﬂex cardiac vagal control with BAT may have
the potential to profoundly impact the outcome of a broad HFrEF
population.
The concept of BAT is to augment the endogenous baroreﬂex activa-
tion from pulsatile distention. In so doing, the deleterious effects of re-
duced BRS should be reversed, thereby improving peripheral blood
ﬂow, reducing RAAS activity and reducing risk of arrhythmia. While
all of these effects have been observed in animal models [6–9], what
can be said of the clinical effects of BAT? In addition to reducing MSNA
and increasing BRS, in our experience with 11 patients BAT improved
NYHA functional class, quality of life asmeasured by theMinnesota Liv-
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also reduced, primarily as a result of reducing the dose of loop diuretics,
implying increased natriuresis. Although it was not a prospective end-
point of our study, we also observed a substantial reduction in accrued
HF-related hospital days in the 6 months following BAT activation as
compared to the 6 months prior to implant. We recently assessed the
long-term beneﬁt of BAT in these patients at an average of 21 months
of follow-up and were impressed to ﬁnd that the normalization of
MSNA and improvements in clinical variables were maintained [10].2. Veriﬁcation and implications for adoption
Abrahamand colleagues have recently reported results [11] of a ran-
domized, controlled trial of BAT in HFrEF which should be of particular
interest to the HF community. The investigators studied surrogate vari-
ables over the course of 6 months in HFrEF patients, measuring treat-
ment effects of BAT patients versus patients receiving optimal medical
management. As with our ﬁrst-in-man experience, NYHA functional
class, QOL and 6MWD all signiﬁcantly improved.While thesemeasures
can be criticized for being susceptible to the placebo effect, the concor-
dant nature of the results both within the randomized trial and in align-
ment with the ﬁrst-in-man study suggests that they are real. Moreover,
the magnitude of improvement in 6 MWD of 58 m is well beyond the
known range of placebo effects for trials of this size [12]. It is also in-
structive to understand the effects of BAT in the context of cardiac
resynchronization therapy (CRT), as it too is an active implantable de-
vice therapy for certain HFrEF patients. In this regard, the magnitude
of QOL improvement exceeded the 95% conﬁdence interval for the
control group in theMIRACLE trial andwas virtually identical to the im-
provement in the MIRACLE CRT arm [13].
Endpoints not known to be susceptible to placebo effects were also
evaluated. Abraham et al. showed a signiﬁcant treatment effect in NT-
proBNP, with a reduction on the order of 25% of baseline values, a
threshold previously cited by Januzzi et al. [14] as indicative of a signif-
icant change in clinical HF severity and of positive physiologic effect.
Similarly, CRT beneﬁcially impacted NT-proBNP in the CARE-HF trial,
demonstrating a comparable improvement [15]. While we did not ob-
serve changes in BNP in our ﬁrst-in-man experience with BAT, this is
likely due to the small sample size and high variability intrinsic to natri-
uretic peptides.
Changes in LVEF also trended toward improvement, with a treat-
ment effect of +2.5%. Reduced availability of interpretable echocardio-
grams likely contributed to the lack of signiﬁcance, as only 89 of an
anticipated 120 patients had evaluable data, in part the result 45% of
patients in the trial having a history of atrial ﬁbrillation. This is in con-
trast to our ﬁrst-in-man experience wherewe observed a signiﬁcant in-
crease in LVEF from 3-dimensional echocardiograms. However, thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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An important difference between the results reported by Abraham
[11] and our experience was that approximately one-third of the
randomized cohort was receiving CRT and yet still remained in NYHA
functional class III, while no such patients were part of the initial
study. The impact of this change in inclusion criteria was assessed in a
prospectively-designed sub-analysis recently reported by Zile and col-
leagues [16]. Statistical analysis of the differences in treatment effect re-
vealed that the patients without CRT responded signiﬁcantly better to
BAT in termsof QOL,MWand LVEF.Within the no-CRT cohort, the treat-
ment effect of BAT was signiﬁcant for the previous variables as well as
NYHA functional class, NT-proBNP and pre- versus post-BAT annualized
HF hospitalization days. Themagnitude of treatment effect was general-
ly higher than what was observed in the main analysis reported by
Abraham et al. [11]. Notably, the no-CRT cohort treatment effect of
BAT for LVEF was+4.4%. This is in line with our observation of LVEF in-
creasing by 3.6% in the ﬁrst-in-man study. It is also similar to the LVEF
increase observed in the CARE-HF treated arm, which improved
+3.6% and +6.9% at 3 and 18 months from CRT initiation, respectively
[15]. In our ﬁrst-in-man study, improved LVEF was driven by signiﬁ-
cantly decreased end-systolic volumes accompanied by a trend toward
reduced end-diastolic volumes, clearly indicating improved ejection.
When detailed echocardiogram data become available for the random-
ized trial it will be interesting to note if similar trends were observed.
Of relevance to improved systolic function, Abraham and colleagues
found a signiﬁcant treatment effect for BAT to improve systolic and
pulse pressures, depression of which is known to predict poor outcome
[17–18]. The pressure changes reached statistical signiﬁcance and were
of a clinically relevant magnitude (systolic BP +8.5 mm Hg (p b 0.03)
BAT vs. −3.8 mm Hg control; pulse pressure + 9.6 mm Hg (p =
0.004) vs.−3.2 mmHg). The increase in systolic pressure was superior
to that observed in CRT-treated arms of the COMPANION trial, where it
was considered a marker of CRT-driven improvement [19]. Pressure in-
creases with BAT also underscore its complementary value to medical
therapy including beta-blockade, which has been shown to provide
beneﬁt independently of pressure [20].Whilemedical therapies address
the hyperadrenergic state of HF, the added beneﬁt with BAT implies that
it enhances therapeutic pathways treated with medical therapy and/or
exploits additional pathways, just as one would expect from its mecha-
nism of action. The trend toward declining pressures in the control arm
of the Abraham study likely reﬂects a progressive worsening of HF that
was avoided in the treatment arm with BAT.
Importantly, pressure increases resulting from BAT occurred with-
out an increase in heart rate and the in presence of reduced sympathetic
activity. In contrast, conventional approaches to improving systolic
pressure with drugs such as dobutamine result in increased myocardial
oxygen demand and, if used chronically, shorten life expectancy.
Although one might expect BAT to chronically decrease heart rate
slightly as it has in animal studies [21], this is less easily achieved clini-
cally due to intensive use of negative chronotropes and rhythm man-
agement interventions. Although the beneﬁts of rate reduction in HF
are undeniable, there are many other potential beneﬁts of restoring
sympathovagal balance beyond those demonstrated in the studies of
BAT to date. These include anti-apoptotic effects, increases in nitric
oxide, reduced damage from ischemia, reduced susceptibility to
arrhythmias and the anti-inﬂammatory reﬂex [22–25].
In addition to improvements in surrogate variables, the use of BAT
was associated with decreased HF hospitalization in both the ﬁrst-in-
man and randomized trials. In the 11 patient cohort, the annualized
rate of hospitalization in the 6 months prior to BAT averaged 2.2 hospi-
talizations/patient/year, while in the 6 months after BAT it was 0.2
(change of−2.0). Likewise, the duration of HF hospitalization was re-
duced from an average of 20.8 days to 6 (change of−14.8). In the ran-
domized trial, no signiﬁcant changes were noted in the control group
while the BAT group conﬁrmed the ﬁrst-in-man ﬁndings withreductions of−0.49 hospitalizations/patient/year and−6.28 days, re-
spectively. Results of the CRT BAT group were attenuated, but the no-
CRT group showed enhanced responses of−0.53 hospitalizations/pa-
tient/year and−8.89 days. These consistent and robust ﬁndings pro-
vide conﬁdence that the restoration of sympathovagal balance by BAT
powerfully impacts HF progression,morbidity, mortality and healthcare
expenditures. Likewise, these impacts bode well for success of the
United States pivotal trial of BAT in HFrEF, which will focus on non-
CRT patients and begin enrollment in the next few months.
It is important to note that the treatment effects within the CRT
group reported by Zile [16] showed clinically signiﬁcant changes in sur-
rogate variables, although with the exception NYHA functional class
they were not statistically signiﬁcant. Although no signal for LVEF was
evident in the CRT group, it is worth recalling that although improve-
ment in LVEF has been postulated as a predictor of long-term response
to therapy in HFrEF, outcomes trials have not uniformly shown agree-
ment between LVEF changes and outcomes, notably BEST, MOXSE and
ELITE [26–28]. In principle, CRT and BAT should complement each
other well: CRT improves pump function while BAT reduces vascular
impedance. Both improve sympathovagal balance and hemodynamics
without increasing myocardial oxygen consumption [29]. Given the
small sample size of the CRT cohort it does not seem appropriate to
rule out theuse of BAT in these patients. In principle BAT andCRT should
be complementary therapies as they both work to improve cardiac out-
put through the twomost important mechanisms, ejection and loading.
Rather, clinical judgment should be applied in light of the patient's his-
tory and knowledge of themechanismof action of BAT. Because changes
in loading can affect synchrony of contraction, it would also be advisable
to consider re-optimizing CRT following BAT optimization. This was not
required in the study of Abraham and colleagues.
Futurework should include a formal evaluation of the impact of BAT
on outcome in HFrEF. This is subject of a large randomized, controlled
trial which will begin enrollment in 2016. BAT has also shown promise
in the treatment of chronic kidney disease, a common comorbidity in
HFrEF. There is, in addition, a strong mechanistic rationale to believe
that BAT may positively impact HFpEF patients [30]. This should be for-
mally investigated.
Lastly, a topic worthy of more study is how best to implement pa-
tient selection. The use of autonomic markers and the recognition of a
high event rate will provide meaningful information in this regard. It
will also be important to further deﬁne the beneﬁts of restoring auto-
nomic balancewith BATwhich are independent of aswell as synergistic
with existing therapies. In this regard, the interaction between BAT and
CRT requires further study. By using both common and complementary
pathways, BAT may provide additional beneﬁts to a guideline-directed
regimen previously limited by suboptimal administration, biological
variation and patient tolerance/compliance.
3. Conclusions
Trials of BAT in HFrEF provide clear evidence of clinical beneﬁt in
NYHA functional class III patients with optimized medical therapy. We
believe the current evidence of long-termbeneﬁt tomorbidity andmor-
tality sufﬁcient to justify widespread adoption of BAT for HFrEF. This is
justiﬁed because the HFrEF trials demonstrate that BAT: (1) is safe,
(2) directly addresses the deranged autonomic balance characteristic
of HF, (3) improves surrogate endpoints, including objective andpredic-
tive measures such as NTproBNP and LVEF, (4) reduces healthcare re-
source utilization (5) has effects which endure for at least 21 months
and (6) has been effectively put into practice at many centers in
Europe and North America.
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